All In Biotech

NDA 204790 · Viiv Hlthcare

Tivicay

Dolutegravir Sodium · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 12, 2013

Approved uses

9

Original approval plus efficacy supplements

Registered trials

306

91 Phase 3, 30 recruiting

FAERS reports

9,026

6,918 serious, 922 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2026.

TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV ‑ 1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) weighing at least 2 kg [see Microbiology ( 12.4 )] . TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. TIVICAY and TIVICAY PD are an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) weighing at least 2 kg. ( 1 ) TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. ( 1 )

Mechanism: Dolutegravir is an HIV-1 antiretroviral agent [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TIVICAY · DOLUTEGRAVIR SODIUM EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • TIVICAY · DOLUTEGRAVIR SODIUM EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • TIVICAY · DOLUTEGRAVIR SODIUM EQ 50MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain1,457
  • anxiety1,059
  • emotional distress1,050
  • anhedonia944
  • chronic kidney disease702
  • exposure during pregnancy655
  • fatigue649
  • headache606
  • off label use584
  • renal failure546
  • rash518
  • foetal exposure during pregnancy483

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
20121
201325
2014366
2015532
2016534
2017563
2018820
20191,135
20201,061
2021926
2022748
2023792
2024766
2025472
2026283

Recalls

3 FDA enforcement reports for this application.

  • May 17, 2024 · Class III · Terminated

    Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

  • May 13, 2022 · Class III · Terminated

    Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

  • Feb 11, 2014 · Class III · Terminated

    Cross Contamination with Other Products: Product contains Promacta (eltrombopag).

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tivicay (Dolutegravir Sodium)

2024 spending

$629M

Beneficiaries

29,205

255,731 claims

Per beneficiary

$21,551

$74.37 per unit

View as table
YearSpending
2020$656,037,862
2021$648,743,459
2022$650,460,654
2023$657,133,269
2024$629,400,836

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 435 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.